drugset / Trial / NCT00754624

An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' Trial

NCT00754624

Phase 2 Completed 229 enrolled Mannkind Corporation
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Safety Follow-Up Trial to PDC-INS-0008 and MKC-TI-005

Timeline

Start
2004-05
Primary completion
2008-06
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Protein / enzyme biologic 15 iu Inhaled
Subject Insulin Protein / enzyme biologic 30 iu Inhaled
Subject Insulin Protein / enzyme biologic 60 iu Inhaled